Literature DB >> 24745333

Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses.

Nicole Joller1, Ester Lozano2, Patrick R Burkett3, Bonny Patel1, Sheng Xiao1, Chen Zhu1, Junrong Xia1, Tze G Tan4, Esen Sefik4, Vijay Yajnik5, Arlene H Sharpe6, Francisco J Quintana1, Diane Mathis4, Christophe Benoist4, David A Hafler2, Vijay K Kuchroo7.   

Abstract

Foxp3(+) T regulatory (Treg) cells regulate immune responses and maintain self-tolerance. Recent work shows that Treg cells are comprised of many subpopulations with specialized regulatory functions. Here we identified Foxp3(+) T cells expressing the coinhibitory molecule TIGIT as a distinct Treg cell subset that specifically suppresses proinflammatory T helper 1 (Th1) and Th17 cell, but not Th2 cell responses. Transcriptional profiling characterized TIGIT(+) Treg cells as an activated Treg cell subset with high expression of Treg signature genes. Ligation of TIGIT on Treg cells induced expression of the effector molecule fibrinogen-like protein 2 (Fgl2), which promoted Treg-cell-mediated suppression of T effector cell proliferation. In addition, Fgl2 was necessary to prevent suppression of Th2 cytokine production in a model of allergic airway inflammation. TIGIT expression therefore identifies a Treg cell subset that demonstrates selectivity for suppression of Th1 and Th17 cell but not Th2 cell responses.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24745333      PMCID: PMC4070748          DOI: 10.1016/j.immuni.2014.02.012

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  33 in total

1.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

2.  Vstm3 is a member of the CD28 family and an important modulator of T-cell function.

Authors:  Steven D Levin; David W Taft; Cameron S Brandt; Christoph Bucher; Edward D Howard; Eric M Chadwick; Janet Johnston; Angela Hammond; Kristen Bontadelli; Daniel Ardourel; LuAnn Hebb; Anitra Wolf; Thomas R Bukowski; Mark W Rixon; Joseph L Kuijper; Craig D Ostrander; James W West; Janine Bilsborough; Brian Fox; Zeren Gao; Wenfeng Xu; Fred Ramsdell; Bruce R Blazar; Katherine E Lewis
Journal:  Eur J Immunol       Date:  2011-03-18       Impact factor: 5.532

3.  The transcription factors Blimp-1 and IRF4 jointly control the differentiation and function of effector regulatory T cells.

Authors:  Erika Cretney; Annie Xin; Wei Shi; Martina Minnich; Frederick Masson; Maria Miasari; Gabrielle T Belz; Gordon K Smyth; Meinrad Busslinger; Stephen L Nutt; Axel Kallies
Journal:  Nat Immunol       Date:  2011-03-06       Impact factor: 25.606

4.  Cutting edge: TIGIT has T cell-intrinsic inhibitory functions.

Authors:  Nicole Joller; Jason P Hafler; Boel Brynedal; Nasim Kassam; Silvia Spoerl; Steven D Levin; Arlene H Sharpe; Vijay K Kuchroo
Journal:  J Immunol       Date:  2011-01-03       Impact factor: 5.422

5.  Regulatory T cell lineage specification by the forkhead transcription factor foxp3.

Authors:  Jason D Fontenot; Jeffrey P Rasmussen; Luke M Williams; James L Dooley; Andrew G Farr; Alexander Y Rudensky
Journal:  Immunity       Date:  2005-03       Impact factor: 31.745

6.  CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner.

Authors:  Ashutosh Chaudhry; Dipayan Rudra; Piper Treuting; Robert M Samstein; Yuqiong Liang; Arnold Kas; Alexander Y Rudensky
Journal:  Science       Date:  2009-10-01       Impact factor: 47.728

7.  Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions.

Authors:  Yeonseok Chung; Shinya Tanaka; Fuliang Chu; Roza I Nurieva; Gustavo J Martinez; Seema Rawal; Yi-Hong Wang; Hoyong Lim; Joseph M Reynolds; Xiao-hui Zhou; Hui-min Fan; Zhong-ming Liu; Sattva S Neelapu; Chen Dong
Journal:  Nat Med       Date:  2011-07-24       Impact factor: 53.440

8.  Foxp3+ follicular regulatory T cells control the germinal center response.

Authors:  Michelle A Linterman; Wim Pierson; Sau K Lee; Axel Kallies; Shimpei Kawamoto; Tim F Rayner; Monika Srivastava; Devina P Divekar; Laura Beaton; Jennifer J Hogan; Sidonia Fagarasan; Adrian Liston; Kenneth G C Smith; Carola G Vinuesa
Journal:  Nat Med       Date:  2011-07-24       Impact factor: 53.440

9.  The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation.

Authors:  Meghan A Koch; Glady's Tucker-Heard; Nikole R Perdue; Justin R Killebrew; Kevin B Urdahl; Daniel J Campbell
Journal:  Nat Immunol       Date:  2009-05-03       Impact factor: 25.606

10.  PD-L1 regulates the development, maintenance, and function of induced regulatory T cells.

Authors:  Loise M Francisco; Victor H Salinas; Keturah E Brown; Vijay K Vanguri; Gordon J Freeman; Vijay K Kuchroo; Arlene H Sharpe
Journal:  J Exp Med       Date:  2009-12-14       Impact factor: 14.307

View more
  290 in total

1.  The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8+ T cell responses.

Authors:  Robert J Johnston; Xin Yu; Jane L Grogan
Journal:  Oncoimmunology       Date:  2015-05-27       Impact factor: 8.110

Review 2.  Negative Regulation of Type 2 Immunity.

Authors:  Dimitri A de Kouchkovsky; Sourav Ghosh; Carla V Rothlin
Journal:  Trends Immunol       Date:  2017-01-09       Impact factor: 16.687

3.  T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.

Authors:  Sarah E Josefsson; Kanutte Huse; Arne Kolstad; Klaus Beiske; Daniela Pende; Chloé B Steen; Else Marit Inderberg; Ole Christian Lingjærde; Bjørn Østenstad; Erlend B Smeland; Ronald Levy; Jonathan M Irish; June H Myklebust
Journal:  Clin Cancer Res       Date:  2017-12-07       Impact factor: 12.531

4.  CD4+CD126low/- Foxp3+ Cell Population Represents a Superior Subset of Regulatory T Cells in Treating Autoimmune Diseases.

Authors:  Ye Chen; Zhenjian Xu; Rongzhen Liang; Julie Wang; Anping Xu; Ning Na; Bin Li; Ruoning Wang; Miller Joseph; Nancy Olsen; Willa Hsueh; Song Guo Zheng
Journal:  Mol Ther       Date:  2020-07-21       Impact factor: 11.454

Review 5.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

6.  Coexpression of TIGIT and FCRL3 identifies Helios+ human memory regulatory T cells.

Authors:  Khalid Bin Dhuban; Eva d'Hennezel; Emil Nashi; Amit Bar-Or; Sadiye Rieder; Ethan M Shevach; Satoshi Nagata; Ciriaco A Piccirillo
Journal:  J Immunol       Date:  2015-03-11       Impact factor: 5.422

Review 7.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

8.  Autophagy-dependent regulatory T cells are critical for the control of graft-versus-host disease.

Authors:  Laëtitia Le Texier; Katie E Lineburg; Benjamin Cao; Cameron McDonald-Hyman; Lucie Leveque-El Mouttie; Jemma Nicholls; Michelle Melino; Blessy C Nalkurthi; Kylie A Alexander; Bianca Teal; Stephen J Blake; Fernando Souza-Fonseca-Guimaraes; Christian R Engwerda; Rachel D Kuns; Steven W Lane; Michele Teng; Charis Teh; Daniel Gray; Andrew D Clouston; Susan K Nilsson; Bruce R Blazar; Geoffrey R Hill; Kelli Pa MacDonald
Journal:  JCI Insight       Date:  2016-09-22

Review 9.  Regulatory T Cells: Central Concepts from Ontogeny to Therapy.

Authors:  Bernard Khor
Journal:  Transfus Med Rev       Date:  2016-07-26

10.  CD70 Inversely Regulates Regulatory T Cells and Invariant NKT Cells and Modulates Type 1 Diabetes in NOD Mice.

Authors:  Cheng Ye; Benjamin E Low; Michael V Wiles; Todd M Brusko; David V Serreze; John P Driver
Journal:  J Immunol       Date:  2020-08-31       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.